



IGFBP-1 EQA (Pre-Term Labour Markers)

WEQAS
Unit 6, Parc Tŷ Glas,
Llanishen
Cardiff, UK
CF14 5DU
Tel: +44 (0) 2920 314750
E-mail: office@weqas.com

INTENDED USE

Weqas IGFBP-1 EQA is for in vitro diagnostic use as an external quality assessment material for testing of IGFBP-1 in cervicovaginal samples of patients with suspected premature rupture of membrane (PROM).

SUMMARY

The use of EQA materials to objectively monitor the accuracy and precision of procedures is well established in clinical laboratories. Weqas IGFBP-1 is EQA material prepared as four different levels covering the clinically relevant range. Each level has a known IGFBP1 concentration and therefore a known qualitative interpretation.

PRODUCT DESCRIPTION

The base material is a phosphate buffered solution containing BSA, protease inhibitors and preservatives which is spiked with pooled amniotic fluid containing semi-purified IGFBP-1. The material is dispensed into 1mL aliquots and stored at -70°C until dispatch, and will thaw in transit.

STORAGE AND STABILITY

The sample should be assayed on the day of receipt and must be brought to ambient temperature (18-30 °C) before analysis.

If you are unable to assay the sample immediately upon receipt, please store between 2-8°C and assay within 5 days.

Samples stored between 2-8°C to analysis must be brought to ambient temperature (18-30 °C) before use.

FREQUENCY

This will be carried out on a bimonthly basis.

STORAGE AND PROCEDURE FOR BATCHED SAMPLES

The samples should be stored at -70°C on receipt. At the start of the return window for each distribution thaw the relevant samples at ambient temperature (18-30 °C) for 24 hours and assay as described in PROCEDURE.

PROCEDURE

The Specimen extraction solution tube is NOT required; the test strip can be placed directly into the EQA sample received.

1. Mix the sample well by inverting 5 to 6 times –ensure there are no air bubbles in the sample.
2. Wear gloves and handle the sample as if it were a normal patient sample ready to analyse for ‘pre-term labour biomarkers’.
3. Carefully remove the lid from the sample.
4. Please follow the test procedure in the ‘Instructions for use’ leaflet in the kit, supplied by the manufacturer.
5. Please ensure to complete all information requested and record results on the return sheet.

Safely dispose of excess sample according to local waste policy guidelines.

ANALYTES COVERED

The Weqas IGFBP-1 EQA samples cover a relevant pathological and analytical range as outlined below.

Analyte
IGFBP-1

LIMITATIONS OF PROCEDURE

The EQA samples supplied require storage as described in STORAGE AND STABILITY and handling as described in PROCEDURE.

Accurate and reproducible results are dependent upon properly functioning instruments and reagents and the use of correct procedures.

! CAUTION !

1. For in vitro diagnostic use only.
2. The base material has been tested in accordance with FDA regulations and found to be negative for HIV Ab, Hep B surface antigen, HCV Ab and RPR.
3. This product should not be disposed of in general waste. Consult local environmental authorities for proper disposal.

Although every effort is made to ensure that the material is free from any known infectious agent, the samples should be handled as for clinical specimens.